METHODS: This was a cross-sectional study that included two PsA cohorts. To identify the DAPSA, PsAID and HAQ-DI thresholds that differentiated patients who reported \"yes\" in response to the PASS question from those who reported \"no,\" we used the receiver operating characteristic curves both for the female and male sexes. Moreover, Cohen\'s kappa test was used to determine the agreement of a PASS \"yes\" with DAPSA ≤ 14, PsAID ≤ 4 and HAQ-DI ≤ 0.5.
RESULTS: Three-hundred ten patients were considered for the study. The DAPSA, PsAID-12 and HAQ-DI thresholds that differentiated PASS \"yes\" patients from PASS \"no\" patients were 11.7, 1.85 and 0.625 in male patients and 13.3, 3.85 and 0.750 in female patients, respectively. A PASS \"yes\" and DAPSA ≤ 14 showed moderate agreement in males (kappa = 0.56) and good agreement in females (kappa = 0.80); the agreement between a PASS \"yes\" and PsAID ≤ 4 and between a PASS \"yes\" and HAQ-DI ≤ 0.5 was higher in female patients (moderate).
CONCLUSIONS: Female patients accept their disease at higher DAPSA, PsAID and HAQ-DI values than male patients do. The clinical meaning of this could be that a female patient generally has a greater global disease acceptance inclination. Therefore, this study further supports the concept that sex differences are present in patients with PsA.
方法:这是一项横断面研究,包括两个PsA队列。为了识别DAPSA,PsAID和HAQ-DI阈值可区分对PASS问题报告“是”的患者与报告“否”的患者,“我们使用了女性和男性的接受者工作特征曲线。此外,Cohen的kappa检验用于确定PASS“是”与DAPSA≤14,PsAID≤4和HAQ-DI≤0.5的一致性。
结果:本研究考虑了三百十例患者。DAPSA,PsAID-12和HAQ-DI区分PASS“是”患者与PASS“否”患者的阈值在男性患者中为11.7、1.85和0.625,在女性患者中为13.3、3.85和0.750,分别。PASS“是”和DAPSA≤14在男性中显示中等一致性(kappa=0.56),在女性中显示良好一致性(kappa=0.80);女性患者(中度)的PASS“是”与PsAID≤4之间以及PASS“是”与HAQ-DI≤0.5之间的一致性较高。
结论:女性患者接受较高DAPSA的疾病,PsAID和HAQ-DI值优于男性患者。其临床意义可能是女性患者通常具有更大的全球疾病接受倾向。因此,这项研究进一步支持了PsA患者存在性别差异的观点.